Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacology of Mupirocin in Nasal Application
NCT06368856Phase 1Active, not recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mupirocin in Staphylococcus aureus colonization (6 arms), sponsored by CHU Saint-Etienne. Primary endpoints: plasma concentrations of mupirocin at 2 hours and intranasal concentrations of mupirocin at 12 hours. Started Feb 2024; status: active, not recruiting.
02
Drugs
mupirocin
03
Conditions
Staphylococcus aureus colonization
Beyond the preview
Go deeper on NCT06368856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368856.